Table 2. Cohort demographic and clinical characteristics.
| Characteristic | Pre-/post-regionalization, n (%) | P value | |
|---|---|---|---|
| 2009–2013 (N=272) | 2014–2016 (N=189) | ||
| Age, median [IQR] | 65 [57–71] | 66 [59–71] | 0.44† |
| Sex | 0.85‡ | ||
| Male | 230 (84.6) | 161 (85.2) | |
| Female | 42 (15.4) | 28 (14.8) | |
| Race | 0.62‡ | ||
| White | 204 (75.0) | 145 (76.7) | |
| Hispanic | 25 (9.2) | 16 (8.5) | |
| Asian/Pacific Islander | 19 (7.0) | 15 (7.9) | |
| Black | 9 (3.3) | 8 (4.2) | |
| Other/unknown | 15 (5.5) | 5 (2.6) | |
| ASA class | 0.03§ | ||
| 1 | 2 (0.7) | 0 (0.0) | |
| 2 | 73 (26.8) | 34 (18.0) | |
| 3 | 170 (62.5) | 141 (74.6) | |
| 4 | 27 (9.9) | 14 (7.4) | |
| Tumor location | 0.63§ | ||
| Gastro-esophageal junction | 111 (40.8) | 73 (38.6) | |
| Lower esophagus | 143 (52.6) | 98 (51.9) | |
| Mid esophagus | 17 (6.3) | 16 (8.5) | |
| Upper esophagus | 1 (0.4) | 2 (1.1) | |
| Morphology | 0.77§ | ||
| Squamous cell carcinoma | 33 (12.1) | 26 (13.8) | |
| Adenocarcinoma | 239 (87.9) | 163 (86.2) | |
| Stage | 0.14‡ | ||
| IA | 49 (18.0) | 21 (11.1) | |
| IB | 23 (8.5) | 13 (6.9) | |
| IIA | 21 (7.7) | 7 (3.7) | |
| IIB | 57 (21.0) | 48 (25.4) | |
| IIIA | 75 (27.6) | 59 (31.2) | |
| IIIB | 25 (9.2) | 19 (10.1) | |
| IIIC | 14 (5.1) | 17 (9.0) | |
| IV | 8 (2.9) | 5 (2.6) | |
| Neoadjuvant treatment (any) | 180 (66.2) | 155 (82.0) | 0.0002‡ |
†, Kruskal-Wallis test; ‡, Chi-square test; §, Fisher’s exact test. IQR, interquartile range; ASA, American Society of Anesthesiologists.